Medivation Inc. (MDVN) and ASTELLAS PHARMA INC.’s (ALPMY) jointly developed drug, Xtandi, is likely to make a dent in the sales of Johnson & Johnson’s (JNJ) drug Zytiga given its more favorable safety profile in treating pre-chemotherapy prostate cancer patients.
By The Burrill Report:
By Vinay Singh
Johnson & Johnson (JNJ) released interim data from a late-stage study that showed its prostate cancer drug, Zytiga, improved survival of men with less advanced forms of the disease. The newly released data may help expand the indication of the already approved drug to treat a larger patient pool.
By John Eastman:As Prostate cancer cases continue to be diagnosed in the U.S. in abundance (estimated 238,590 new cases of prostate cancer will be diagnosed with nearly 30,000 deaths) drug makers are also intensifying their effort to confront this late stage of life disease in men. The average age at the time of diagnostics is 67.
ByEmerging Equities:According to research firm RNCOS, the number of newly diagnosed global cancer cases is expected to reach over 17 million by 2020. The U.S. is the largest market for cancer drugs.
Increasing Prevalence Calls for New Treatment Options